Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) just unveiled an announcement.
Sihuan Pharmaceutical Holdings Group has disclosed the 2025 annual results of its non-wholly owned subsidiary Xuanzhu Biopharmaceutical, which is also listed in Hong Kong. The move informs shareholders and investors about the financial performance of the innovative drug unit, which remains in an investment-heavy stage.
Xuanzhu Biopharm’s revenue rose to RMB51.8 million in 2025 from RMB30.1 million a year earlier, with gross profit more than doubling to RMB33.4 million. Despite this growth, the subsidiary reported a narrowed but still substantial net loss of RMB245.5 million, reflecting continued high R&D and operating expenses as it advances its biopharma pipeline.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is a Hong Kong-listed pharmaceutical company with operations in innovative drug research and development through subsidiaries such as Xuanzhu Biopharmaceutical. The group focuses on developing and commercializing biopharmaceutical products in the Chinese market, leveraging its R&D capabilities to build a pipeline of new therapies.
YTD Price Performance: 10.57%
Average Trading Volume: 33,215,199
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.69B
For an in-depth examination of 0460 stock, go to TipRanks’ Overview page.